Literature DB >> 30207742

Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics.

Fabiana de Sousa Cunha1, Laise Nayra Dos Santos Pereira2, Thâmara Pryscilla de Costa E Silva2, Roberto Alves de Sousa Luz2, Anderson Nogueira Mendes2,3.   

Abstract

The use of nanoparticulate systems with action in breast and ovarian cancer has been highlighted in recent years as an alternative to increasing the therapeutic index of conventional anticancer drugs. Thus, nanoparticles have advantageous characteristics in the treatment of cancer. Several nanocarriers of drugs and nanoparticles are described in the literature. The pharmacokinetics of the drugs can be modified by the use of nanocarriers, which in turn facilitate the specific delivery of the drug to the tumour cell. Therefore, the present work is a review that examines some nanosystems with nanoparticles for action in the treatment of breast cancer and ovarian cancer.

Entities:  

Keywords:  Nanomedicine; breast cancer; nanocarriers; ovarian cancer; theranostics

Year:  2018        PMID: 30207742     DOI: 10.1080/1061186X.2018.1523418

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  3 in total

1.  Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs.

Authors:  Huan Tang; Yizhuo Xie; Ming Zhu; Juan Jia; Rui Liu; Yujia Shen; Yucui Zheng; Xin Guo; Dongfanghui Miao; Jin Pei
Journal:  Int J Nanomedicine       Date:  2022-07-07

Review 2.  The Application of Carbon Nanomaterials in Sensing, Imaging, Drug Delivery and Therapy for Gynecologic Cancers: An Overview.

Authors:  Changji Xiao; Changming Li; Jun Hu; Lirong Zhu
Journal:  Molecules       Date:  2022-07-13       Impact factor: 4.927

Review 3.  A Review on Nanocarrier Mediated Treatment and Management of Triple Negative Breast Cancer: A Saudi Arabian Scenario.

Authors:  Insha Nahvi; Sana Belkahla; Supratim Biswas; Suparna Chakraborty
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.